Grace Therapeutics (GRCE) Research & Development (2015 - 2026)
Grace Therapeutics (GRCE) reported Research & Development of $885,000 for fiscal Q2 2027 (quarter ended Sep 30, 2026), up 55.8% from $568,000 a year earlier and up 27.0% from the prior quarter.
Grace Therapeutics (GRCE) Research & Development (2015 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, Grace Therapeutics' Research & Development came in at $2.46 million, down 54.0% year-over-year; for FY2026 (ended Mar 31, 2026), it was $2.41 million, down 74.7% from FY2025.
- Research & Development has a five-year compound annual growth rate of -10.4% (FY2021 to FY2026).
- By fiscal year, Research & Development came in at $9.51 million in FY2025 (+103.1%), $4.68 million in FY2024 (-53.0%), $9.97 million in FY2023 (+79.4%) and $5.56 million in FY2022 (+33.2%).
- The fiscal Q2 2027 figure ranks as the highest quarterly Research & Development since fiscal Q1 2026.
- Year over year, Research & Development gained in two of the last eight quarters, with an average decline of 27.6%.
- The high point for year-over-year Research & Development in five years was fiscal Q2 2025 (growth of 547.0%); the low point was fiscal Q2 2024 (a decline of 86.0%).
- Per Business Quant data, the three fiscal quarters before Q2 2027 came in at $697,000 (Q1 2027), $420,000 (Q4 2026) and $462,000 (Q3 2026).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,276.89 Bn | 1,250.50 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 681.31 Bn | 601.18 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 520.63 Bn | 488.64 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 357.22 Bn | 320.16 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 310.90 Bn | 284.14 Bn | - | - |
| 6 | Astrazeneca | 285.12 Bn | 258.77 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 250.23 Bn | 201.89 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 207.56 Bn | 182.67 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 164.42 Bn | 111.77 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Grace Therapeutics | 35.10 Mn | -35.61 Mn | - | 885,000.00 |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 885,000.00 |
| Jun 30, 2026 | 697,000.00 |
| Mar 31, 2026 | 420,000.00 |
| Dec 31, 2025 | 462,000.00 |
| Sep 30, 2025 | 568,000.00 |
| Jun 30, 2025 | 955,000.00 |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 460,000.00 |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Sep 30, 2022 | 3.29 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.33 Mn |
| Dec 31, 2021 | 2.18 Mn |
Grace Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=GRCE&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "GRCE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=GRCE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();